Ibrahim Turkoz

Senior Researcher, Janssen Pharmaceuticals, Inc.

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Ibrahim Turkoz appears in 8 tracked papers (2021–2025), most studied alongside Esketamine, Ketamine and Placebo, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Safety & Risk Management.

Most-cited paper: Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior (81 citations).

Frequent co-authors: Jaskaran Singh, Ella Daly and Daniel Fu.

Background & Research

Ibrahim Turkoz is a researcher at Janssen Pharmaceuticals / Janssen Research & Development in Titusville, New Jersey, where he has worked on clinical and real-world analyses in psychiatry. His publications include studies of esketamine nasal spray for treatment-resistant depression, dissociation, safety, and outcomes in acute suicidal ideation or behavior.

Key Impact

He is a psychiatric drug-development researcher whose work appears on multiple esketamine studies in treatment-resistant depression and suicidal ideation, contributing to the evidence base for rapid-acting antidepressant treatments.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

13 collaborators· click a node to visit their profile

Full network →

Compounds

EsketamineKetaminePlacebo

Topics

Depressive DisordersTreatment-Resistant Depression (TRD)Safety & Risk ManagementMajor Depressive Disorder (MDD)SuicidalityAnxiety DisordersSchizophreniaOlder AdultsHeadache Disorders (Cluster & Migraine)Chronic PainSubstance Use Disorders (SUD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Ibrahim Turkoz is associated with.

Janssen Pharmaceuticals, Inc.

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

View stakeholder →

Janssen Scientific Affairs, LLC

View stakeholder →

Janssen Research & Development

pharma

Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.

View stakeholder →